Navigation Links
VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
Date:9/1/2011

MOUNTAIN VIEW, Calif., Sept. 1, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug application (NDA) for its investigational drug candidate, avanafil, for the treatment of erectile dysfunction (ED). The target date for the FDA to complete its review of the avanafil NDA is April 29, 2012. In previously announced results from the pivotal phase 3 trials, patients treated with avanafil achieved significant improvement in erectile function compared to placebo. The avanafil development program included over 1,350 patients and avanafil was shown to be well tolerated and effective in treating patients with general ED and diabetics with ED. The long-term safety study also confirmed the results observed in the phase 3 studies.

"We are pleased with FDA's acceptance of our NDA. If approved, avanafil could be a valuable treatment alternative for the 18 million men in the United States that suffer from ED," stated Peter Y. Tam, president of VIVUS.

About AvanafilAvanafil is an investigational oral medication being developed for the treatment of erectile dysfunction.  Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian Pacific Rim countries.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL,
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
2. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
3. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
4. VIVUS to Present at Three Upcoming Investor Conferences in March
5. VIVUS Provides Regulatory Update on QNEXA NDA
6. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
7. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
10. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
11. VIVUS Announces Sale of MUSE Assets to Meda
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... SAN DIEGO, March 2, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... fourth quarter and full year ended December 31, 2014. Financial ... and a net loss of $5.3 million, or $0.04 per ... net loss of $22.0 million, or $0.19 per share, for ... year 2014 include revenues of $75.3 million and a net ...
(Date:3/2/2015)... Biomedical, Inc., a leading processor of human tissue, synthetics, ... it hired Lou Barnes as President and ... formed UMTB Biomedical as a wholly-owned subsidiary to acquire ... 2014. UMTB is the oldest tissue bank in the ... veteran of the tissue banking industry, having most recently ...
(Date:3/2/2015)...  Akron Children,s Hospital has been designated a Diagnostic ... of Radiology (ACR), making it the first hospital in ... hospital in the United States ... from the ACR as a DICOE provides validation that ... with national benchmarks," says Dr. Michael Rubin , ...
Breaking Medicine Technology:Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 2Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 3Akron Children's designated ACR Diagnostic Imaging Center of Excellence 2
... CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer ... the IVD testing market, was featured in Medical ... article by Amanda Petersen, titled "CardioGenics aims to offer ... Yahia Gawad, MD regarding the company,s point-of-care (POC) cardiac ...
... to watch their favorite television programs, sports and news while ... FLO TV(TM) Personal Television hits shelves across the nation today. ... owned subsidiary of Qualcomm Incorporated (Nasdaq: QCOM ), delivers ... mobile TV service and will be available at Amazon.com ...
Cached Medicine Technology:CardioGenics Holdings Inc. Featured in Medical Device Daily 2CardioGenics Holdings Inc. Featured in Medical Device Daily 3Television Enthusiasts Can Get Their TV Fix as FLO TV Personal Television Mobile Device Debuts with Major Retailers 2Television Enthusiasts Can Get Their TV Fix as FLO TV Personal Television Mobile Device Debuts with Major Retailers 3
(Date:3/2/2015)... The Workgroup for Electronic Data Interchange (WEDI), ... health IT to create efficiencies in healthcare information exchange, ... Providers.” The white paper by WEDI’s ICD-10 Testing Subworkgroup ... testing by focusing on primary considerations and steps for ... October 1, 2015 implementation date. Download the white ...
(Date:3/2/2015)... The minimally invasive surgical instruments market ... 6.1% to reach $14,133.0 million by 2019 from ... as advantages of minimally invasive surgeries over traditional ... invasive surgeries and increasing number of surgical procedures ... minimally invasive surgical instruments market. , For More ...
(Date:3/2/2015)... Houston, TX (PRWEB) March 02, 2015 ... a lot easier thanks to the success of ... making meal planning easy and delicious for thousands ... overwhelmingly positive customer feedback by expanding to offer ... Traditional Tastes, which features seasonally appropriate classic recipes ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Regulatory ... focused on quality, regulatory and technical consulting, announces ... Chief Operating Officer. , Before joining RCA, ... leading R&D teams in all aspects of developing ... positions at Covidien (Medtronic), Regulatory Compliance Associates Inc., ...
(Date:3/2/2015)... 2015 What are the best practices ... references? When are interviews scheduled, how can physicians best ... training and practicing physicians who are looking for new ... more at the PracticeLink Physician Career Advancement Workshop and ... Fair is from 5:30 to 8:30 p.m. at the ...
Breaking Medicine News(10 mins):Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 3Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2
... 11 Nordic Naturals announces,their new Spa Collection, ... formulas: Omega Radiance(TM) and Omega Therapi(TM). Based on,Norwegian ... the hair and skin with omega-3 and omega-6 ... optimal results. Omega-3s and omega-6s,are considered essential because ...
... from Caring.com, baby boomers caring for an aging parent are playing an ... , ... San Mateo, Calif. (PRWEB) November 11, 2008 -- According to a ... playing an active role when it comes to decisions about their parents, ...
... RX" documents how an entire era of children ... unprecedented change in Western culture: that of drugging ... ever before, according to the producers. This dynamic ... of the most ,respected names in Hollywood, including ...
... National Alzheimer,s Disease Awareness Month--The Apo E Gene ... Alzheimer,s Disease, and Other Chronic Illnesses. ,THE APO ... in "Health: Diet and Weight Loss" category of ... Book News,The APO E Gene Diet presents an ...
... Launches National Multimedia Project Aimed at Preventing,Treating, and ... 11 Every 21 seconds someone in,America sustains ... more,than 19 percent of military personnel returning from ... mild to severe brain trauma., To view ...
... Inc.,s parent,company, Team Finance LLC (the "Company") today ... 2008., The Company previously announced the decision ... substantially completed the disposal,of this business line during ... accounting guidance, the results of the anesthesia management,business ...
Cached Medicine News:Health News:Nordic Naturals Offers Radiant Beauty From the Inside Out With New Spa Collection of Essential Fatty Acid Supplements 2Health News:Boomers Play an Active Role with Parent's Medication Decisions 2Health News:Kevin P. Miller's Film "Generation RX" Reveals Widespread Ethical Conflicts, Risks of Psychiatric Drugs to Children 2Health News:Kevin P. Miller's Film "Generation RX" Reveals Widespread Ethical Conflicts, Risks of Psychiatric Drugs to Children 3Health News:The Apo E Gene Diet--Preventing, Alzheimer's and Heart Disease, One Patient at a Time 2Health News:The Apo E Gene Diet--Preventing, Alzheimer's and Heart Disease, One Patient at a Time 3Health News:The Apo E Gene Diet--Preventing, Alzheimer's and Heart Disease, One Patient at a Time 4Health News:Video: BrainLine.org Confronts Traumatic Brain Injury Crisis 2Health News:Team Finance LLC Announces Third Quarter 2008 Results 2Health News:Team Finance LLC Announces Third Quarter 2008 Results 3Health News:Team Finance LLC Announces Third Quarter 2008 Results 4Health News:Team Finance LLC Announces Third Quarter 2008 Results 5Health News:Team Finance LLC Announces Third Quarter 2008 Results 6Health News:Team Finance LLC Announces Third Quarter 2008 Results 7Health News:Team Finance LLC Announces Third Quarter 2008 Results 8Health News:Team Finance LLC Announces Third Quarter 2008 Results 9
Provides maximum comfort upon insertion through ultra-smooth catheter eyelets--formed with advanced ultrasonic technology....
... cost-effective method of providing patient warming while ... warming tube is ideal for use in ... Radiology. The CSZ Warming Tube is the ... it may be used in almost any ...
... Our patient warming system consists of ... a range of blankets for use ... all clinical applications. Blankets are available ... adult and paediatric sizes and a ...
... is the automated benchtop solution for nucleic ... extensive integrated features and a sample throughput ... the system meets the demanding nucleic acid ... to medium sample throughput., ,The high-quality nucleic ...
Medicine Products: